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Abstract
Background: The data from cohorts of childhood-onset granulomatosis with polyangiitis (GPA) and microscopic
polyangiitis (MPA) remain scarce and heterogeneous. We aimed to analyse the features at presentation, therapeutic
approaches and the disease course of these rare diseases.
Methods: Electronic searches of Medline and the Cochrane Central Register of Controlled trials database were
conducted. We also checked the reference lists of the studies included and other systematic reviews, to identify
additional reports. We included all cohorts, cross-sectional studies or registries reporting features at presentation or
outcomes in patients with a diagnosis of childhood-onset GPA or MPA (age <18 years). The pooled prevalence of
clinical manifestations at presentation, ANCA and induction therapies for GPA and MPA was calculated.
Results: We reviewed 570 full texts and identified 14 studies on GPA and 8 on MPA. Childhood-onset GPA and
MPA occurred predominantly in female subjects during adolescence. For GPA, ear-nose-throat (ENT) disease (pooled
prevalence 82 % [95 % CI 78–87]), constitutional symptoms (73 % [95 % CI 55–88]), renal (65 % [95 % CI 49–79]),
and lower respiratory tract (61 % [95 % CI 48–74]) manifestations were the most frequently reported at
presentation. Renal disease was a hallmark of MPA (94 % [95 % CI 89–97]). ANCA were detected in >90 % of
children with GPA or MPA. Combined corticosteroids and cyclophosphamide was the most frequently used first
remission-inducing treatment for GPA (76 % [95 % CI 69–82]) and MPA (62 % [95 % CI 20–96]). Relapses occurred
more frequently in GPA (67–100 %) than in MPA (25–50 %). The leading causes of death were the disease itself, and
infections.
Conclusions: Childhood-onset MPA and GPA remain severe diseases with frequent relapses and a high cumulative
morbidity. Survival and disease-free survival need to be improved.
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Background
Systemic vasculitis in children accounts for 2 to 10 % of
the conditions evaluated in paediatric rheumatology
clinics [1, 2]. IgA vasculitis and Kawasaki disease are the
most common [3], whereas childhood-onset anti-
neutrophil cytoplasmic antibody (ANCA)-associated vas-
culitis (AAV), including granulomatosis with polyangiitis
(GPA, Wegener’s), eosinophilic granulomatosis with po-
lyangiitis (EGPA, Churg-Strauss) and microscopic poly-
angiitis (MPA) are more rare. Our knowledge of these
diseases is based mostly on small cohort studies or, more
frequently, case series or reports. Since the development
of the first specific paediatric classification of vasculitis
by the European League Against Rheumatism (EULAR)
and the Paediatric Rheumatology European Society
(PReS) in 2006 [4], the number of cohorts of patients
with paediatric AAV, mostly GPA, reported has steadily
increased [5–12].
Nevertheless, the data from such cohorts remain
scarce and heterogeneous, and no attempt has yet been
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made to outline the main features of these rare diseases
more precisely.
We conducted a systematic literature review and
meta-analysis: 1) to summarize the principal clinical and
demographic features on presentation; 2) to describe the
course of the disease and 3) to describe the therapeutic
approaches reported for children with GPA and MPA.
Methods
Literature search
We performed a systematic literature review and a meta-
analysis, to obtain a best estimate of the prevalence of
clinical manifestations at presentation and to review the
treatments given to patients with childhood-onset GPA
and MPA. The Meta-analyses of Observational Studies in
Epidemiology (MOOSE) guidelines were followed [13].
We conducted a literature search on Medline and the
Cochrane Central Register of Controlled trials database
from January 1, 1950 to December 31, 2015, as reported
on Additional file 1. We also checked the reference lists of
the studies included and other systematic reviews on the
topic, to identify additional reports.
Inclusion criteria and procedure
We included all cohorts, cross-sectional studies or regis-
tries reporting data for features at presentation or out-
comes in patients with a diagnosis of childhood-onset
GPA or MPA (age <18 years). All papers providing a base-
line description of the study population were considered.
Studies reporting only data for specific subgroups of
patients (e.g. only patients with nephritis) were excluded.
The titles and abstracts of all the references identified
were reviewed independently by two of the authors (MI,
XP). The full text of the articles considered potentially
relevant was then screened and checked for eligibility.
Any disagreements about article inclusion were resolved
at this stage.
Data extraction
We used standardized data extraction forms. We re-
corded the clinical manifestations at diagnosis, and the
number of patients with at least one clinical manifest-
ation within each organ/system domain, if specified. If
the authors reported only the number of patients with a
particular single clinical manifestation but not the sum
of patients with at least one manifestation within a do-
main (e.g. the number of patients with lung nodules etc.,
but not the total number of patients with respiratory in-
volvement), we used the lowest estimate for the pooling
of prevalence data. Clinical manifestations that were not
described were considered to be absent.
Remission and relapses were defined according to
EULAR recommendations [14]. We checked the
accuracy of data extraction, and any inconsistencies were
discussed and resolved.
Quality scoring
Two authors independently rated each paper for the risk
of bias, based on the Methodological Evaluation of
Observational research checklist, which was adapted for
the specific research question [15] (Additional file 2).
Statistical analyses
All point estimates of analyses and their 95 % confidence
intervals (95 % CI) were calculated by inverse variance
weighting. Heterogeneity was assessed by carrying out χ2
tests on Cochran’s Q statistic and by calculating I2. If het-
erogeneity was high (I2 > 50 %), we used random-effect
models. Forest plots were constructed. We considered p-
values <0.05 to be statistically significant. Data were ana-
lysed with MetaXL (MetaXL 1.3, EpiGear International
Brisbane). We did not use funnel plots to assess publica-
tion bias because this technique was not applicable [16].
Results
Literature search
The literature search identified 570 hits in PubMed, and
0 in the Cochrane Library (Additional file 3). Thirty-
three articles were considered to be potentially relevant.
Another 12 potentially relevant articles were identified
by an additional search and by screening the references
of the included articles. Overall, we included 14 studies
on GPA and eight on MPA.
Granulomatosis with polyangiitis
Characteristics of the studies included
We analysed data from 13 retrospective studies [5–7, 9–12,
17–22] and one prospective cohort [23]. One study in-
cluded two 20-year-old patients [17] and another used an
upper limit of 19 years for the definition of childhood-onset
AAV [23], but we decided to retain these studies in the ana-
lysis to prevent the loss of useful information. In total, data
for 294 patients (69 % girls) were included. The main char-
acteristics of studies included are summarised in Table 1.
Risk of bias
The most frequent sources of bias were the sampling
framework and the case definition for GPA, followed by
patient selection (Additional file 2: Tables S1 and S2).
Clinical and laboratory features on entry into the study
Thirteen of the 14 studies included assessed the features
of the patients on entry into the study [5–7, 9–12, 17–19,
21–23]. These studies included 277 patients in total: 145/
194 (75 %) were Caucasian (data available for seven stud-
ies), with a median age at disease onset of 11.6 years (data
available for seven studies) and a median age at diagnosis
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USA Canada Iran Serbia France France UK UK USA International Poland
Year of
publication
2000 2009 1993 2007 2013 2013 2015 2015 2011 1998 1978 2014 2014
Years of
enrolment
NA since 2004 NA 1984–2005 2002–2011 1992–2011 1965–2014 1986–2011 1996–2010 1986–1991 1952–1976 2000–2010 1995–2013











Retrospective Retrospective Retrospective Retrospective Retrospective Retrospective Retrospective Retrospective
Number of
patients
7 65 23 25 11 3 25 28 7 12 6 56 9
Ethnicity (n) Caucasian 41 Caucasian,







NA White 21/25 NA NA 19
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21 Caucasian 5 Caucasian,
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Table 1 Main characteristics of the studies on childhood-onset granulomatosis with polyangiitis and features of the patients at presentation (Continued)
pANCA positivity
(ELISA), n (%)
1/7 (14.2) 8 (12.3) NA NA 2 (18) 1 (33.3) 4/18 (22.2) 6/28 (21.4) NA 6 (50.0) NA 13/50 (26.0) NA
cANCA positivity
(IFI), n (%)
NA 43 (66.2) NA 13/15 (86.7) 11 (100) 2 (66.6) 12/20 (60.0) NA 4/7 (57.1) 6 (50.0) NA NA NA
pANCA positivity
(IFI), n (%)





7 (100) 58 (89.2) 5 (71.4) 24 (96.0) 9 (81.8) 3 (100) 17 (68.0) 23 (82.1) 3 (42.8) 0 5 (83.3) 50 (89.2) 8 (88.8)
Mucocutaneous,
n (%)
2 (28.5) 23 (35.4) 2 (8.6) 8 (32.0) 3 (27.2) 3 (100) 6 (24.0) 15 (53.5) 4 (57.1) 10 (83.3) 3 (50.0) 36 (64.2) 4 (44.4)
Musculoskeletal,
n (%)
4 (57.1) 37 (56.9) 7 (30.4) 24 (96.0) 3 (27.2) 2 (66.6) 9 (36.0) 16 (57.1) 5 (71.4) 9 (75.0) 2 (33.3) 33 (58.9) 3 (33.3)




7 (100) 52 (80.0) 20 (87) 21 (84.0) 8 (72.7) 2 (33.3) 21 (84.0) 21 (75.0) 4 (57.1) 11 (91.6) 6 (100) 51 (91.0) 5 (55.5)
Respiratory,
n (%)
6 (85.7) 52 (80.0) 5 (21.7) 20 (80.0) 2 (18.1) 0 17 (68.0) 19 (67.8) 3 (42.8) 7 (58.3) 5 (83.3) 44 (78.5) 7 (77.7)
Cardiovascular,
n (%)
0 0 2 (8.7) 5 (20.0) 1 (9.0) 0 0 0 0 0 0 0 0
Gastrointestinal,
n (%)
0 27 (41.5) 0 3 (12.0) 3 (27.2) 0 5 (20.0) 5 (17.8) 1 (14.2) 6 (50.0) 0 9 (16.0) 5 (55.5)
Neurological,
n (%)
0 16 (24.6) 1 (4.3) 2 (8.0) 1 (9.0) 0 1 (4.0) 1 (3.5) 1 (14.2) 2 (16.6) 1 (16.6) 8 (14.2) 1 (11.1)
Renal, n (%) 7 (100) 49 (75.4) 2 (8.6) 22 (88.0) 4 (36.3) 3 (100) 9 (36.0) 22 (78.5) 4 (57.1) 4 (33.3) 5 (83.3) 38 (67.8) 8 (88.8)
Treatment
Oral GCs ± IS,
n (%)
7 (100) 60 (92.3) 23 (100) 25 (100) NA 3 (100) 21 (84.0) 28 (100) NA NA 5 (83.3) NA 9 (100)
GCs ± CYC,
n (%)
6 (85.7) 54 (83.0) 18 (78.2) 15 (60.0) NA 3 (100) 18 (72.0) NA NA NA 3 (50.0) NA 9 (100)
GCs ± MTX,
n (%)
0 7 (10.7) 1 (4.3) 5 (20.0) NA 0 2 (8.0) NA NA NA 0 NA 0
GCs ± AZA,
n (%)
0 0 2 (8.6) 0 NA 0 2 (8.0) NA NA NA 0 NA 0
Plasmapheresis,
n (%)
4 (57.1) 9 (13.8) 0 0 NA 1 (33.3) 1 (4.0) NA NA NA 0 NA 0














of 14 years (range: 4–17) (data available for six studies).
Prevalence for the involvement of each organ/system is
shown in Table 2.
ENT system involvement was the most frequent mani-
festation observed, followed by constitutional symptoms,
renal, lower respiratory tract, musculoskeletal and cuta-
neous involvement (Fig. 1). Mild heterogeneity was ob-
served only for ENT and neurologic involvement.
None of the patients had baseline gangrene or retinal vas-
culitis, two of the “major” clinical manifestations according
to the modified Birmingham Vasculitis Activity Score [24].
CNS (central nervous system) involvement occurred in 3 %
(95 % CI 1–7 %; I2 = 31 %) of patients, but no detailed infor-
mation was provided. Other major manifestations included
scleritis/episcleritis in 2 % (95 % CI 1–4 %; I2 = 43 %), ische-
mic abdominal pain in 2 % (95 % CI 1–4 %; I2 = 64 %),
haemoptysis/alveolar haemorrhage in 16 % (95 % CI 6–
29 %; I2 = 84 %), and renal problems requiring dialysis in
2 % (95 % CI 1–5 %; I2 = 48 %) of patients. Subglottic sten-
osis and saddle nose were observed at presentation in 9 %
(95 % CI 6–12 %; I2 = 0 %) and 5 % (95 % CI 1–11 %; I2 =
64 %) of patients, respectively, and lung nodules were ob-
served in 10 % of patients (95 % CI 2–22 %; I2 = 84 %).
A sensitivity analysis was performed. We first excluded
the two studies including adult patients [7, 11], with no
major impact on prevalence estimates and then the
nephrology surveys [12, 19], resulting in a lower preva-
lence of renal disease at admission (Additional file 4:
Table S5). Following the grouping of studies by
geographic origin (Europe or North America), we found
that the prevalence of skin manifestations was higher in
Europe (prevalence 55 % [95 % CI 32–76] vs. 28 % [95 %
CI 14–45 %]; p = 0.01) [7, 10–12, 18, 19, 22], whereas
the prevalence of neurological involvement was higher
in studies from North America [5, 6, 17, 23] (17 % [95 %
CI 10–24] vs. 7 % [95 % CI 2–14]; p = 0.043).
Seven studies provided information about ANCA de-
tection by immunofluorescence methods [5–7, 11, 17,
21, 22]. Positive results were obtained for c-ANCA in
71 % (95 % CI 56–84, I2 = 59 %), and for p-ANCA in
20 % (95 % CI 13–27, I2 = 0 %) of patients. The esti-
mated prevalence of anti-PR3 (proteinase 3) antibodies
was 69 % (95 % CI 58–80, I2 = 60 %), whereas that of
anti-MPO (myeloperoxidase) antibodies was 21 % (95 %
CI 16–27, I2 = 25 %) (data available from 9 studies) [5, 6,
9, 11, 12, 18, 19, 21, 22].
Induction therapies and drug-related adverse events
The drugs used for induction therapy were reported in
nine studies [5, 6, 10–12, 17, 19, 22, 23]. Corticosteroids
were the most prescribed drugs (prevalence 95 %; 95 % CI
92–98; I2 = 35 %), but it was not possible to determine the
dose most frequently used. Immunosuppressants were
also used (in monotherapy or with corticosteroids): cyclo-
phosphamide in 76 % (95 % CI 69–82; I2 = 27 %) of pa-
tients, methotrexate in 10 % (95 % CI 6–16; I2 = 0 %),
azathioprine in 2 % (95 % CI 0–5; I2 = 26 %) and plasma-
pheresis in 8 % of patients (95 % CI 1–21; I2 = 72 %). With
the exception of plasmapheresis, immunosuppression pro-
tocols were very similar between studies. The other drugs
used for induction therapy included immunoglobulins,
cyclosporine, colchicine and rituximab.
The principal drug-related adverse events reported
were infections. Infertility, hemorragic cystitis, cataracts,
glaucoma, osteoporosis, steroid myopathy, Cushing syn-
drome, and depression were also reported. Growth re-
tardation was observed in two studies [5, 20], but not
confirmed in a third one [11]. Only one case of breast
cancer diagnosed at age of 30 was reported.
Follow-up data for cumulative clinical manifestations,
relapse, and survival
At least one item of information about the course of the dis-
ease was reported in 11 articles [5, 7, 10–12, 17, 19–23].
The duration of the observation period was reported in four
studies, and ranged from 2.7 to 18.5 years [5, 7, 11, 23]. At
Table 2 Prevalence for the involvement of each organ/system at first consultation in childhood-onset granulomatosis with polyangiitis
and microscopic polyangiitis
Organ/system ENT Systemic Renal Lower respiratory
tract




82 73 65 61 55 44 24 19 13 4
95 % CI 78–87 55–88 49–79 48–74 43–67 32–57 15–34 10–30 9–17 1–9




3 79 94 37 57 44 7 28 18 2
95 % CI 1–7 65–90 89–97 24–52 27–86 27–61 3–11 17–41 7–34 0–5
I2 0 64 47 67 89 73 0 55 72 0
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Fig. 1 Pooled prevalence for the most frequent organ/system involvement at first consultation in childhood-onset granulomatosis with polyangiitis
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least one relapse occurred in 67 to 100 % of patients. Sur-
vival data were available for 161 patients: 14 of these patients
died (at a mean age (±SD) of 18 ± 11 years; based on data
for eight patients), from sepsis in two patients, fungal infec-
tion in one, pulmonary haemorrhage in three, chronic lung
disease due to GPA in two, multiple-organ failure in one,
and a heroin overdose in one. Cumulative incidence was 91
to 100 % for ENT involvement, up to 48 % for subglottic
stenosis, up to 60 % for ocular disease and up to 88 % for
renal involvement.
Microscopic polyangiitis
Literature search and characteristics of the studies
included
We analysed data from eight retrospective cohorts [11, 12,
25–30] for a total of 130 patients (86/109 patients were
female [79 %]). The main organ/system involvement are
summarised in Table 2 and the main characteristics of
studies included in Table 3.
Risk of bias
The most frequent source of bias was the sampling frame-
work for MPA, followed by patient selection and the def-
inition of MPA (Additional file 2: Tables S3 and S4).
Clinical and laboratory features on entry into the study
For the 130 MPA patients identified, median age was
10.5 years at disease onset (data available for four studies)
and 12 years at diagnosis (data available for three studies).
Renal disease was the most frequent manifestation on
presentation, followed by systemic features, musculoskeletal,
cutaneous, lower respiratory tract and gastrointestinal sys-
tem involvement (Table 2). Heterogeneity between studies
was low for renal, ENT, ocular, and cardiovascular involve-
ment (Fig. 2). Lung infiltrates (18 % [95 % CI 6–35]; I2 =
77 %) and alveolar haemorrhage (18 %, [95 % CI 5–35]; I2 =
77 %) occurred at similar frequencies. ENT involvement
was limited to sinusitis. Seizures were the most frequent
neurological manifestation (5 % [95 % CI 2–9]; I2 = 44 %)
and purpura was the most frequent skin lesion (10 % [95 %
CI 0–27]; I2 = 86 %).
Following the grouping of the studies by geographic
region of origin (Europe or Asia), we found that the
prevalence of skin manifestations (66 % [95 % CI 28–96]
vs. 29 % [95 % CI 19–40]; p = 0.02) was higher in studies
from Europe [11, 12, 25, 27] (Additional file 4: Table S6).
Information about immunofluorescence findings for
ANCA positivity was available in five studies [11, 25,
28–30]. Positive results were obtained for c-ANCA in
4 % of patients (95 % CI 1–11, I2 = 50 %), and for p-
ANCA in 94 % of patients (95 % CI 86–99, I2 = 35 %).
The prevalence of anti-MPO antibodies was 93 % (95 %
CI 83–99, I2 = 52 %), that of anti-PR3 antibodies was 5 %
(95 % CI 1–11, I2 = 0 %) (data from 8 studies) [11, 12,
25, 27–29].
Induction therapies and drug-related adverse events
Six studies reported the drugs used to induce remission
[11, 25, 27–30]. In five of these studies, oral or intraven-
ous cyclophosphamide was used with corticosteroids
(62 %, 95 % CI 20–96, I2 = 90 %). In one study [30], only
rituximab was used. If we excluded this study from the
analysis, the prevalence of cyclophosphamide use in-
creased to 77 % (95 % CI 45–99, I2 82 %). In one study
[27], plasmapheresis was also performed. No detailed in-
formation about drug-related adverse events during
follow-up was provided. One study stated that no cases
of impaired fertility or cancer occurred during follow-up
[29]. In another, only infections were described [30].
Follow-up data for cumulative clinical manifestations,
relapse, and survival
Follow-up data were reported in seven articles [11, 12, 25,
27–30]. The duration of the observation period was re-
ported in six studies, and ranged from 4 to 55 months. At
least one relapse occurred in 25 to 50 % of the patients
(total of 63 patients from four studies) [11, 12, 25, 30].
Twenty-nine patients (22 %) developed end-stage renal
disease or a need for dialysis during follow-up. All studies
provided survival data. Six children died: one from the
rupture of a hepatic aneurysm, one from pulmonary infec-
tion, one from cytomegalovirus infection, and no informa-
tion was available for the other patients.
Discussion
We conducted this study to provide a better definition
of the principal manifestations of childhood-onset GPA
and MPA at presentation and their course over time.
This study is the first to use a systematic approach in-
cluding a meta-analysis to analyse these rare paediatric
conditions for which a small number of essentially retro-
spective studies have been published to date.
We confirmed the female predominance of GPA and
MPA in children. About 70 % of the GPA patients and
80 % of the MPA patients were girls. This finding con-
trasts with those for studies in adults, which have reported
an absence of difference in frequency between the sexes
or a slightly higher frequency in men for [31–33]. We also
confirmed that most of these paediatric cases were diag-
nosed in adolescence.
As expected, the principal manifestations at disease
onset were those involving the respiratory tract in pa-
tients with GPA and the kidney in patients with MPA.
ENT involvement was rare in MPA, but was the most
frequent clinical feature at presentation in GPA patients.
It is, therefore, a potentially useful additional sign for
distinguishing between these two conditions. Saddle
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Table 3 Main characteristics of the studies on childhood-onset microscopic polyangiitis and features of the patients at presentation
















Year of publication 2015 2015 2001 2006 2015 2014 2001 2006
Years of enrolment 1965–2014 1986–2011 1990–1999 1998–2003 2011–2014 2003–2013 1990–1997 1998–2004
Study design Retrospective Retrospective Retrospective Retrospective Retrospective Retrospective Retrospective Retrospective
Number of patients 4 38 10 7 11 20 21 19
Ethnicity 3 Caucasian, 1
Asian
26 (68 %) Caucasian NA NA NA NA NA NA
Female, number (%) 0 34 (89) 6 (60) 6 (86) 6 (54) 16 (80) NA 18 (95)
Median age at onset NA NA NA 12 (7–15) 7.6 (4.3–11.8) 10 (1.9–16.8) NA 10.8 ± 2.8





According to Watts et
al. [40]
Typical biopsy findings











cANCA positivity (ELISA) 1/1 4/38 0 NA 0 2/17 NA 0
pANCA positivity (ELISA) 0/1 33/38 10 (100) 7 (100) 11 16/17 NA 19/19
cANCA positivity (IFI) 1/2 0 0 NA 0 2/20 NA 0
pANCA positivity (IFI) 1/2 NA 9 (90) NA 10/10 18/20 NA 19/19
Clinical manifestations
Systemic 4 (100.0) 29 (78.0) 10 (100.0) 7 (100.0) 8 (72.7) 10 (50.0) 18 (85.7) 12 (63.1)
Mucocutaneous 2 (50.0) 13 (34.2) 7 (70.0) 7 (100.0) 3 (27.2) 3 (15.0) 8 (38.0) 6 (31.5)
Musculoskeletal 2 (50.0) 11 (28.9) 6/9 (66.7) 7 (100.0) 11 (100.0) 2 (10.0) 7 (33.0) 0
Ocular 0 3 (7.8) 0 0 0 1 (5.0) 2 (9.5) 1 (5.2)
Ear, nose, and throat 0 0 0 0 0 0 2 (9.5) 2 (10.5)
Respiratory 0 11 (28.9) 3 (30.0) 4 (57.1) 5 (45.4) 3 (15.0) 13 (61.9) 10 (52.6)
Cardiovascular 1 (25.0) 0 0 0 1 (9.0) 0 0 0
Gastrointestinal 2 (50.0) 4 (10.5) 2/9 (22.2) 4 (57.1) 2 (18.1) 3 (15.0) 7 (33.3) 9 (47.3)
Neurological 2 (50.0) 2 (5.2) 2/9 (22.2) 6 (85.7) 1 (9.0) 3 (15.0) 1 (4.7) 1 (5.2)
Renal 4 (100.0) 36 (94.7) 7 (70.0) 7 (100) 11 (100.0) 16 (100.0) 21 (100.0) 19 (100.0)













Fig. 2 Pooled prevalence for the most frequent organ/system involvement at first consultation in childhood-onset microscopic polyangiitis
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nose was already present at presentation in 5 % of GPA
patients, confirming previous observations of a higher rate
of this complication in children [20, 23, 32]. Sinusitis was
the only ENT feature observed in patients with MPA.
Renal disease was the leading feature of MPA, and was
observed at onset in almost all children. However, as
most of the surveys included were carried out at neph-
rology centres, there may have been a referral bias. As
for GPA, the data from the different cohorts were highly
heterogeneous, but renal impairment was diagnosed in
about 65 % of patients at presentation. This observation
suggests that childhood GPA, when diagnosed, is a mul-
tisystem disease rather than a condition “limited” to the
upper airways, as proposed in the past [23, 34]. In
addition, renal disease is not very common at presenta-
tion in adults (17 % of patients in the study by Hoffman
et al. [31]) but it generally occurs during the course of
the disease. By contrast, it seems to have a much higher
incidence at disease onset in children. Moreover, one
fifth of the children with MPA displayed progression to
ESRD (end-stage renal disease) or a need for dialysis
during follow-up, highlighting the severity of renal dis-
ease in these children.
In addition to the principal specific manifestations ob-
served at presentation in GPA and MPA patients, systemic
features were also frequent in three-quarters of patients at
presentation and half the patients presented musculoskel-
etal symptoms, as also highlighted by a recently published
study by the ARChiVe Investigator Network [35]. Eye
problems were rare, but were more frequent in GPA than
in MPA, whereas gastrointestinal involvement was more
frequent in MPA than in GPA patients. Cardiomyopathy
was described in only two patients, both with MPA.
Special attention should be paid to alveolar haemorrhage
and subglottic stenosis, which may be life-threatening.
Alveolar haemorrhage was not rare at disease presentation
in either MPA or GPA, being observed in about 18 % of
patients. Subglottic stenosis was observed only in GPA pa-
tients. Early reports suggested that the incidence of subglot-
tic stenosis was higher in children with GPA than in adults.
Rottem et al. [23] found that about 40 % of patients devel-
oped subglottic stenosis during 8 years of follow-up, corre-
sponding to rates five times higher than reported in adult
surveys [23]. These data, together with those from a UK co-
hort [20], led to the inclusion of subglottic stenosis in the
paediatric classification criteria [4]. Our results give a more
precise estimate of the impact of this complication on the
course of paediatric GPA. The available data show that a
fairly uniform proportion of paediatric cases (9 %) already
display subglottic stenosis at presentation. By contrast, inci-
dence was found to vary considerably over time. Cumulative
incidence ranged from 16 % [11] to 40–48 % in studies with
similar follow-up periods [8, 20, 23]. Overall, these data con-
firm the previous finding of a higher risk of subglottic
stenosis in children than in adults, in whom a cumulative
prevalence of 10 % has been reported [36].
A large proportion of the patients tested detected posi-
tive for ANCA. Only one MPA patient with anti-PR3
antibodies was reported. However, one fifth of the GPA
patients tested positive for anti-MPO antibodies, and
this proportion was similar in all studies. The high
prevalence of ANCA in children as compared to adults
should be borne in mind when paediatricians are consid-
ering a diagnosis of one of these diseases.
A number of different treatment regimens were used,
but the drugs used to treat GPA differed little between
studies, reflecting a relatively uniform approach to the
induction of remission over the long time period cov-
ered by this meta-analysis. Most of the information
about treatment provided by the available reports con-
cerned “traditional” drugs, with rituximab treatment re-
ported in only one patient. This is consistent with the
approval of rituximab registration for induction treat-
ment in adult patients with GPA and MPA by the FDA
in 2011 and by the EMA in 2013. Reports pointing out a
good response to rituximab are rapidly increasing.
Cyclophosphamide was the drug most frequently used
to treat patients with MPA, and a protocol based on ri-
tuximab and mycophenolate mofetil was considered as a
first-line treatment in only one study, on 11 patients
[30]. In this study, 90 % of the patients were in complete
remission at the last follow-up visit.
The paucity of available information made it impos-
sible to define the course of the disease with any degree
of precision. For example, a detailed assessment of dis-
ease activity over time is lacking. This could have been
favoured by the delay in drawing up a specific index for
paediatric conditions [37]. However, the available data
suggest that most GPA patients experience at least one
relapse, whereas disease flares are observed in less than
half of all MPA patients. However, end-stage renal dis-
ease was a particular problem in children with MPA.
About one fifth of the children with MPA presented
ESRD, whereas the proportion of GPA patients present-
ing this condition was much lower. As in adults [38], the
development of new therapeutic strategies should help
to improve disease-free survival.
The burden of drug-related adverse effects was well
described only in papers on GPA. The most frequent
problems encountered were infections, followed by dam-
age due to chronic corticosteroid and cyclophosphamide
treatments. The data relating to growth retardation in
GPA patients were inconsistent.
Overall, 7 % of the patients for whom follow-up data
were available died during follow-up, mostly from
disease-related and infectious complications. Respiratory
complications were the leading causes of disease-related
death in children with GPA. These data confirm that
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GPA and MPA diseases in children are severe and diffi-
cult to manage. Long-term survival remains a matter of
concern and should be assessed in future reports.
This study has several limitations. First, determining
the prevalence of clinical manifestations at the onset of
AAV was not the main objective in most of the primary
studies. So despite the fact that we used a broad search
strategy, it is likely that we missed some relevant studies
reporting these data. The large number of additional ar-
ticles identified by manual searching is consistent with
this hypothesis. Moreover, we cannot exclude the possi-
bility that the descriptions of the features of patients at
presentation were not always exhaustive. There was also
considerable heterogeneity, which was explored through
subgroup analysis, although it should be borne in mind
that such analyses are known to be subject to certain
limitations. Finally, at least one monogenic disease asso-
ciated with early-onset polyarteritis nodosa such as
ADA2 (Adenosine deaminase 2) deficiency has recently
been described [39] and other monogenic disorders cor-
responding to some cases of childhood-onset AAV with
a narrower range of clinical features and a specific drug-
response pattern may be discovered in the near future.
Conclusion
We found that the incidence of childhood GPA and MPA
was higher in girls than in boys, with most cases diagnosed
during adolescence. Renal disease was the main feature at
presentation in patients with MPA, whereas ENT was the
predominant feature in patients with GPA. Childhood-onset
GPA was associated with a higher prevalence of renal
disease and nasal deformities at presentation and a higher
overall incidence of subglottic stenosis over time than GPA
in adults. Relapses were more frequently observed in pa-
tients with GPA than in those with MPA, and the leading
causes of death were related to the disease itself or to infec-
tions. Further improvements in survival and disease-free
survival are required in these severe paediatric diseases.
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